Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial
Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4...
Gespeichert in:
| Veröffentlicht in: | The Journal of pediatrics 1986-12, Vol.109 (6), p.936-943 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 943 |
|---|---|
| container_issue | 6 |
| container_start_page | 936 |
| container_title | The Journal of pediatrics |
| container_volume | 109 |
| creator | Rosenfeld, Ron G. Hintz, Raymond L. Johanson, Ann J. Brasel, Jo Anne Burstein, Stephen Chernausek, Steven D. Clabots, Teresa Frane, James Gotlin, Ronald W. Kuntze, Joyce Lippe, Barbara M. Mahoney, Patrick C. Moore, Wayne V. New, Maria I. Saenger, Paul Stoner, Elizabeth Sybert, Virginia |
| description | Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (−0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height. |
| doi_str_mv | 10.1016/S0022-3476(86)80272-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77175125</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022347686802724</els_id><sourcerecordid>77175125</sourcerecordid><originalsourceid>FETCH-LOGICAL-c484t-9564a821db1c58c03dbb1d44d2b86ffed65562f21217e88f0ed66abfefd1de563</originalsourceid><addsrcrecordid>eNqFkE2PFCEQQInRrOPqT9iEgzF6aAUaaNrLxmz8StZo4nomNBQOhm5G6F53_PXSzmSumxAIVa-K4iF0QclrSqh8850QxpqWd_Klkq8UYR1r-AO0oaTvGqna9iHanJDH6EkpvwghPSfkDJ21ou0Y7zfo7gvM25CmfcTbZTQT_pnTn3mLtymPaQJsJofTXd1zius9TPhmyRNkXPZrcIS3-FuGGMYwmbzHGcoS54KTxwbvcio7sHO4BZxrjzSGv-DwnIOJT9Ejb2KBZ8fzHP348P7m6lNz_fXj56t3143lis9NLyQ3ilE3UCuUJa0bBuo4d2xQ0ntwUgjJPKOMdqCUJzUizeDBO-pAyPYcvTj0rcP8XqDMegzFQoxmgrQU3XW0E5SJCooDaOvUJYPXuxzG-idNiV6N6__G9apTq7pW45rXuovjA8swgjtVHRXX_PNj3hRroq8ibCgnTLVSsJ7ejxHF-YpdHjCozm4DZF1sgMmCC7ma1i6Fe-b9B9DxrPA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77175125</pqid></control><display><type>article</type><title>Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Rosenfeld, Ron G. ; Hintz, Raymond L. ; Johanson, Ann J. ; Brasel, Jo Anne ; Burstein, Stephen ; Chernausek, Steven D. ; Clabots, Teresa ; Frane, James ; Gotlin, Ronald W. ; Kuntze, Joyce ; Lippe, Barbara M. ; Mahoney, Patrick C. ; Moore, Wayne V. ; New, Maria I. ; Saenger, Paul ; Stoner, Elizabeth ; Sybert, Virginia</creator><creatorcontrib>Rosenfeld, Ron G. ; Hintz, Raymond L. ; Johanson, Ann J. ; Brasel, Jo Anne ; Burstein, Stephen ; Chernausek, Steven D. ; Clabots, Teresa ; Frane, James ; Gotlin, Ronald W. ; Kuntze, Joyce ; Lippe, Barbara M. ; Mahoney, Patrick C. ; Moore, Wayne V. ; New, Maria I. ; Saenger, Paul ; Stoner, Elizabeth ; Sybert, Virginia</creatorcontrib><description>Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (−0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height.</description><identifier>ISSN: 0022-3476</identifier><identifier>EISSN: 1097-6833</identifier><identifier>DOI: 10.1016/S0022-3476(86)80272-4</identifier><identifier>PMID: 3537249</identifier><identifier>CODEN: JOPDAB</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Adolescent ; Adult ; Age Determination by Skeleton ; Applied sciences ; Biological and medical sciences ; Body Height - drug effects ; Child ; Child, Preschool ; Clinical Trials as Topic ; Drug Therapy, Combination ; Exact sciences and technology ; Female ; Growth - drug effects ; Growth Hormone - analogs & derivatives ; Growth Hormone - therapeutic use ; Hormones - therapeutic use ; Hormones. Endocrine system ; Human Growth Hormone ; Humans ; Insulin-Like Growth Factor I - blood ; Medical sciences ; Other techniques and industries ; Oxandrolone - therapeutic use ; Pharmacology. Drug treatments ; Prospective Studies ; Random Allocation ; Recombinant Proteins - therapeutic use ; Turner Syndrome - drug therapy</subject><ispartof>The Journal of pediatrics, 1986-12, Vol.109 (6), p.936-943</ispartof><rights>1986</rights><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c484t-9564a821db1c58c03dbb1d44d2b86ffed65562f21217e88f0ed66abfefd1de563</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0022-3476(86)80272-4$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8308441$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8365291$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3537249$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosenfeld, Ron G.</creatorcontrib><creatorcontrib>Hintz, Raymond L.</creatorcontrib><creatorcontrib>Johanson, Ann J.</creatorcontrib><creatorcontrib>Brasel, Jo Anne</creatorcontrib><creatorcontrib>Burstein, Stephen</creatorcontrib><creatorcontrib>Chernausek, Steven D.</creatorcontrib><creatorcontrib>Clabots, Teresa</creatorcontrib><creatorcontrib>Frane, James</creatorcontrib><creatorcontrib>Gotlin, Ronald W.</creatorcontrib><creatorcontrib>Kuntze, Joyce</creatorcontrib><creatorcontrib>Lippe, Barbara M.</creatorcontrib><creatorcontrib>Mahoney, Patrick C.</creatorcontrib><creatorcontrib>Moore, Wayne V.</creatorcontrib><creatorcontrib>New, Maria I.</creatorcontrib><creatorcontrib>Saenger, Paul</creatorcontrib><creatorcontrib>Stoner, Elizabeth</creatorcontrib><creatorcontrib>Sybert, Virginia</creatorcontrib><title>Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial</title><title>The Journal of pediatrics</title><addtitle>J Pediatr</addtitle><description>Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (−0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Determination by Skeleton</subject><subject>Applied sciences</subject><subject>Biological and medical sciences</subject><subject>Body Height - drug effects</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Clinical Trials as Topic</subject><subject>Drug Therapy, Combination</subject><subject>Exact sciences and technology</subject><subject>Female</subject><subject>Growth - drug effects</subject><subject>Growth Hormone - analogs & derivatives</subject><subject>Growth Hormone - therapeutic use</subject><subject>Hormones - therapeutic use</subject><subject>Hormones. Endocrine system</subject><subject>Human Growth Hormone</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor I - blood</subject><subject>Medical sciences</subject><subject>Other techniques and industries</subject><subject>Oxandrolone - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Random Allocation</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Turner Syndrome - drug therapy</subject><issn>0022-3476</issn><issn>1097-6833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE2PFCEQQInRrOPqT9iEgzF6aAUaaNrLxmz8StZo4nomNBQOhm5G6F53_PXSzmSumxAIVa-K4iF0QclrSqh8850QxpqWd_Klkq8UYR1r-AO0oaTvGqna9iHanJDH6EkpvwghPSfkDJ21ou0Y7zfo7gvM25CmfcTbZTQT_pnTn3mLtymPaQJsJofTXd1zius9TPhmyRNkXPZrcIS3-FuGGMYwmbzHGcoS54KTxwbvcio7sHO4BZxrjzSGv-DwnIOJT9Ejb2KBZ8fzHP348P7m6lNz_fXj56t3143lis9NLyQ3ilE3UCuUJa0bBuo4d2xQ0ntwUgjJPKOMdqCUJzUizeDBO-pAyPYcvTj0rcP8XqDMegzFQoxmgrQU3XW0E5SJCooDaOvUJYPXuxzG-idNiV6N6__G9apTq7pW45rXuovjA8swgjtVHRXX_PNj3hRroq8ibCgnTLVSsJ7ejxHF-YpdHjCozm4DZF1sgMmCC7ma1i6Fe-b9B9DxrPA</recordid><startdate>19861201</startdate><enddate>19861201</enddate><creator>Rosenfeld, Ron G.</creator><creator>Hintz, Raymond L.</creator><creator>Johanson, Ann J.</creator><creator>Brasel, Jo Anne</creator><creator>Burstein, Stephen</creator><creator>Chernausek, Steven D.</creator><creator>Clabots, Teresa</creator><creator>Frane, James</creator><creator>Gotlin, Ronald W.</creator><creator>Kuntze, Joyce</creator><creator>Lippe, Barbara M.</creator><creator>Mahoney, Patrick C.</creator><creator>Moore, Wayne V.</creator><creator>New, Maria I.</creator><creator>Saenger, Paul</creator><creator>Stoner, Elizabeth</creator><creator>Sybert, Virginia</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19861201</creationdate><title>Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial</title><author>Rosenfeld, Ron G. ; Hintz, Raymond L. ; Johanson, Ann J. ; Brasel, Jo Anne ; Burstein, Stephen ; Chernausek, Steven D. ; Clabots, Teresa ; Frane, James ; Gotlin, Ronald W. ; Kuntze, Joyce ; Lippe, Barbara M. ; Mahoney, Patrick C. ; Moore, Wayne V. ; New, Maria I. ; Saenger, Paul ; Stoner, Elizabeth ; Sybert, Virginia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c484t-9564a821db1c58c03dbb1d44d2b86ffed65562f21217e88f0ed66abfefd1de563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Determination by Skeleton</topic><topic>Applied sciences</topic><topic>Biological and medical sciences</topic><topic>Body Height - drug effects</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Clinical Trials as Topic</topic><topic>Drug Therapy, Combination</topic><topic>Exact sciences and technology</topic><topic>Female</topic><topic>Growth - drug effects</topic><topic>Growth Hormone - analogs & derivatives</topic><topic>Growth Hormone - therapeutic use</topic><topic>Hormones - therapeutic use</topic><topic>Hormones. Endocrine system</topic><topic>Human Growth Hormone</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor I - blood</topic><topic>Medical sciences</topic><topic>Other techniques and industries</topic><topic>Oxandrolone - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Random Allocation</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Turner Syndrome - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosenfeld, Ron G.</creatorcontrib><creatorcontrib>Hintz, Raymond L.</creatorcontrib><creatorcontrib>Johanson, Ann J.</creatorcontrib><creatorcontrib>Brasel, Jo Anne</creatorcontrib><creatorcontrib>Burstein, Stephen</creatorcontrib><creatorcontrib>Chernausek, Steven D.</creatorcontrib><creatorcontrib>Clabots, Teresa</creatorcontrib><creatorcontrib>Frane, James</creatorcontrib><creatorcontrib>Gotlin, Ronald W.</creatorcontrib><creatorcontrib>Kuntze, Joyce</creatorcontrib><creatorcontrib>Lippe, Barbara M.</creatorcontrib><creatorcontrib>Mahoney, Patrick C.</creatorcontrib><creatorcontrib>Moore, Wayne V.</creatorcontrib><creatorcontrib>New, Maria I.</creatorcontrib><creatorcontrib>Saenger, Paul</creatorcontrib><creatorcontrib>Stoner, Elizabeth</creatorcontrib><creatorcontrib>Sybert, Virginia</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosenfeld, Ron G.</au><au>Hintz, Raymond L.</au><au>Johanson, Ann J.</au><au>Brasel, Jo Anne</au><au>Burstein, Stephen</au><au>Chernausek, Steven D.</au><au>Clabots, Teresa</au><au>Frane, James</au><au>Gotlin, Ronald W.</au><au>Kuntze, Joyce</au><au>Lippe, Barbara M.</au><au>Mahoney, Patrick C.</au><au>Moore, Wayne V.</au><au>New, Maria I.</au><au>Saenger, Paul</au><au>Stoner, Elizabeth</au><au>Sybert, Virginia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial</atitle><jtitle>The Journal of pediatrics</jtitle><addtitle>J Pediatr</addtitle><date>1986-12-01</date><risdate>1986</risdate><volume>109</volume><issue>6</issue><spage>936</spage><epage>943</epage><pages>936-943</pages><issn>0022-3476</issn><eissn>1097-6833</eissn><coden>JOPDAB</coden><abstract>Seventy girls with Turner syndrome, 4 to 12 years of age, were randomly assigned to receive either no treatment (control) or methionyl human growth hormone (0.125 mg/kg three times per week), oxandrolone (0.125 mg/kg/day), or combination hGH plus oxandrolone therapy. Baseline growth rates averaged 4.3 cm/yr, and all were within 2 SD of mean growth velocity for age in giris with Turner syndrome. Sixty-seven giris remained in the study for a minimum of 1 year. Growth rates and growth velocity (in standard deviations for age in girls with Turner syndrome) were control 3.8 cm/yr (−0.1 SD), hGH 6.6 cm/yr (+2.3 SD), oxandrolone 7.9 cm/yr (+3.7 SD), and combination therapy 9.8 cm/yr (+5.4 SD). Mean bone ages advanced 1.0 years (hGH), 1.3 years (oxandrolone), and 1.6 years (combination). However, median increments in height age/bone age (ΔHA/ΔBA) ratios ranged from 1.0 to 1.1 for treatment groups, compared with 0.8 for the controls. Predicted adult height by the method of Bayley-Pinneau increased 2.5 cm for hGH or oxandrolone alone, and 3.2 cm for combination treatment. These data indicate that both hGH and oxandrolone can significantly stimulate short-term skeletal growth in patients with Turner syndrome, and potentially increase final adult height.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>3537249</pmid><doi>10.1016/S0022-3476(86)80272-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3476 |
| ispartof | The Journal of pediatrics, 1986-12, Vol.109 (6), p.936-943 |
| issn | 0022-3476 1097-6833 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77175125 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adolescent Adult Age Determination by Skeleton Applied sciences Biological and medical sciences Body Height - drug effects Child Child, Preschool Clinical Trials as Topic Drug Therapy, Combination Exact sciences and technology Female Growth - drug effects Growth Hormone - analogs & derivatives Growth Hormone - therapeutic use Hormones - therapeutic use Hormones. Endocrine system Human Growth Hormone Humans Insulin-Like Growth Factor I - blood Medical sciences Other techniques and industries Oxandrolone - therapeutic use Pharmacology. Drug treatments Prospective Studies Random Allocation Recombinant Proteins - therapeutic use Turner Syndrome - drug therapy |
| title | Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T12%3A41%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methionyl%20human%20growth%20hormone%20and%20oxandrolone%20in%20Turner%20syndrome:%20Preliminary%20results%20of%20a%20prospective%20randomized%20trial&rft.jtitle=The%20Journal%20of%20pediatrics&rft.au=Rosenfeld,%20Ron%20G.&rft.date=1986-12-01&rft.volume=109&rft.issue=6&rft.spage=936&rft.epage=943&rft.pages=936-943&rft.issn=0022-3476&rft.eissn=1097-6833&rft.coden=JOPDAB&rft_id=info:doi/10.1016/S0022-3476(86)80272-4&rft_dat=%3Cproquest_cross%3E77175125%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77175125&rft_id=info:pmid/3537249&rft_els_id=S0022347686802724&rfr_iscdi=true |